THE Washington Consensus is in my view was something of a Schrodinger's Cat. Alive when the West were telling others to ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Goldman Sachs raised the firm’s price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company’s Q3 results and announced deal with Novartis (NVS) involving ...

A research team in China has held atoms in a state of quantum superposition for 23 minutes, suggesting tantalizing new ...

In a significant stride within the pharmaceutical industry, Midtown's own Schrödinger has clinched a deal with healthcare ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple ...

Despite a decline in total revenue, Schrodinger Inc (SDGR) strengthens its financial position with a major Novartis ...

Leerink Partners has recently initiated Schrodinger Inc (SDGR) stock to Outperform rating, as announced on July 2, 2024, according to Finviz. Earlier, on December 5, 2023, KeyBanc Capital Markets had ...

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago. These figures ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 14.78% ...

The stock of Schrodinger Inc (NASDAQ: SDGR) has increased by 0.09 when compared to last closing price of 17.58. Despite this, the company has experienced a -0.65% fall in its stock price over the last ...